Teplizumab  (Synonyms: 泰普利单抗; MGA-031; PRV-031)

Teplizumab (MGA-031) is a Fc receptor non-binding anti-human CD3 monoclonal antibody. Teplizumab reduces the loss of beta-cell function. Teplizumab can be used in the research of type 1 diabetes^[1][2].

Human IgG1 kappa

Human IgG1 kappa, Isotype Control

Humanized

CD3^[1]

Teplizumab (10 ng/mL-10 μg/mL, 5 days) induces human CD8+ T-cell proliferation^[3].
Teplizumab (6 days) increases the expression of CD25 and intracellular CTLA4 on CD8+ cells (freshly isolated PBMCs)^[3].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Teplizumab (0.24 mg/kg, i.p.) induces migration of human CD4 T cells to the lamina propria and ablated the treatment effects of the drug on graft survival in NSG mice^[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

876387-05-2

液体

Colorless to light yellow

泰普利单抗

Shipping with dry ice.

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  Human IgG1 kappa

• 
  Immobilized Human CD3D&CD3E can bind Teplizumab. The EC₅₀ for this effect is 102.5 ng/mL.

• [1]. Kevan C Herold, et al. An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes. N Engl J Med. 2019 Aug 15;381(7):603-613.  [Content Brief]

  [2]. Frank Waldron-Lynch, et al. I Analysis of FcR non-binding anti-CD3 mAb in humanized mice identifies novel human gut tropic cells with regulatory function that are found in patients. Sci Transl Med. 2012 Jan 25;4(118):118ra12.  [Content Brief]

  [3]. Brygida Bisikirska, et al. TCR stimulation with modified anti-CD3 mAb expands CD8+ T cell population and induces CD8+CD25+ Tregs. J Clin Invest. 2005 Oct;115(10):2904-13.  [Content Brief]